Genentech, Inc. South San Francisco California USA
Citations 1
99 | FIXED DURATION SUBCUTANEOUS MOSUNETUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM THE PHASE II MORNINGSUN STUDY
Hematological Oncology | June 17, 2025 | Volume: 43 | Issue: S3 | Pages: No page available